Skip Navigation

Resident Publications Since 2007

73 papers from residents and fellows


  1. Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep;18(3):229-36. doi: 10.1038/pcan.2015.22.
  2. Samuels SE, Vainshtein J, Spector ME, Ibrahim M, McHugh JB, Tao Y, Schipper M,Worden F, Eisbruch A. Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemo-radiotherapy. Radiother Oncol 2015;116:75-81.
  3. Samuels SE, Eisbruch A, Beitler JJ, Corry J, Bradford CR, Saba NF, van den Brekel MWM, Smee R, Strojan P, Suarez C, Mendenhall WM, Takes RP, Rodrigo JP, Haigentz M, Rapidis AD, Rinaldo A, Ferlito A. Clinical Review:  Management of Locally Advanced HPV Related Oropharyngeal Squamous Cell Carcinoma:  Where are we? Eur Arch Otorhinolaryngol. 2015 Oct 13
  4. Vainshtein JM, Samuels SE, Tao Y, Lyden T, Haxer M, Schipper M, Eisbruch A. Impact of Xerostomia on Dysphagia after Chemo-IMRT for Oropharyngeal Cancer: Prospective longitudinal study. 2015 Head & Neck
  5. Samuels SE, Lyden T, Haxer M, Spector ME, Tao Y, Schipper M, Worden F, Eisbruch A. Comparisons of Dysphagia and Quality of Life (QoL) in Matched Patients with HPV-positive Oropharyngeal Cancer Receiving Chemo-irradiation or Cetuximab-irradiation.  2015 Oral Oncology
  6. Issa M, Samuels SE, Bellile E, Shalabi F, Eisbruch A, Wolf G. Tumor volumes and   prognosis in laryngeal cancer. Cancers (Basel) 2015 Nov 10;7(4):2236-61
  7. Jolly S, Soni P, Gaffney DK, Biagioli M, Elshaikh MA, Jhingran A, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Wahl AO, Williams NL, Yashar CM, Small W Jr. ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer. Oncology. 2015 Nov;29(11):867-72, 874-5
  8. Paravati AJ, Hawkins PG, Martin AN, Mansy G, Rahn DA, Advani SJ, Hoisak J, Dragojevic I, Martin PJ, Miller CJ, Sanghvi P. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e659-64. doi: 10.1016/j.prro.2015.07.002. Epub 2015 Jul 17. PMID: 26432680


  1. Liss AL. Ben-David MA. Jagsi R. Hayman JA. Griffith KA. Moran JM. Marsh RB. Pierce LJ. Decline of Cosmetic Outcomes Following Accelerated Partial Breast Irradiation Using Intensity-Modulated Radiotherapy: Results of a Single Institution Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):96-102.
  2. Liss AL. Ooi CH. Zjablovskaja P. Benoukraf T. Radomska H. Ju C. Wu M. Balastik M. Delwel RH. Brdicka T. Tan P. Tenen DG. Alberich-Jorda M. The Gene Signature in CCAAT-Enhancer-Binding Protein α Dysfunctional Acute Myeloid Leukemia Predicts Responsiveness to Histone Deacetylase Inhibitors. Haematologica. 2014 Apr;99(4):697-705.
  3. Samuels SE, Stenmark MH, Hayman JA, Orringer MB, Urba SG, Sun L, Xie C, KongFM, Cuneo KC. Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: treatment related mortality and long-term outcomes.  ASTRO 2014 Oral presentation.


  1. Liss AL. Abu-Isa EI. Jawad MS. Feng FY. Vance SM. Winfield RJ. Narayana V. Sandler HM. McLaughlin PW. Hamstra DA. Combination Therapy Improves Prostate Cancer Survival for Patients with Potentially Lethal Prostate Cancer: The Impact of Gleason Pattern 5. Manuscript in preparation.
  2. McLaughlin PW. Liss AL. American College of Radiology (ACR) Appropriateness Criteria for Locally Advanced (High-Risk) Prostate Cancer. Manuscript in review by ACR panel.
  3. Liss AL. Narayan V. Evans C. Murgic J. McLaughlin PW. Variation in External Sphincter Extension Within and Beyond the Prostate: Implications from MRI Based Post Implant Segmental Dosimetry. Manuscript in preparation.
  4. Varlotto J. Fakiris A. Flickinger J. Medford-Davis L. Liss AL. Shelkey J. Belani C. DeLuca J. Recht A. Maheshwari N. DeCamp M. Matched-Pair and Propensity Score Comparisons of Outcomes of Patients with Clinical Stage I Non-Small Cell Lung Cancer Treated with Resection or Stereotactic Radiosurgery. Cancer. 2013 Aug 1;119(15):2683-91
    Kapadia NS, Bobiak S, Zornosa C, D’Amico T, Pisters K, Dexter B, Niland J, Hayman J. SBRT And Surgery For Stage I NSCLC are Associated with Comparably Low Rates Of Acute Toxicity. ASTRO, 2013.
  5. S Han, JC. Brenner, A Sabolch, W Jackson, C Speers, K Wilder-Romans, KE. Knudsen, TS. Lawrence, AM. Chinnaiyan, FY. Feng, Targeted radiosensitization of ETS fusion-postiive prostate cancer via PARP1 inhibition, Neoplasia, Oct 2013, in press
  6. S Johnson, W Jackson, C Speers, FY Feng, D Hamstra, The Prognostic Utility of the Stephenson Nomogram on Freedom From Biochemical Failure, Freedom From Metastasis and Prostate Cancer-specific Survival Following Salvage Radiotherapy For Prostate Cancer, Strahlen Onkol., Oct 2013, in review
  7. Samuels SE, Matuszak MM, Arenberg D, Stanton P, Wang J, Ten Haken RK, Hayman JA, Curtis J, Kong FM.  Changes in DLCO Instead of FEV1 During Treatment are Correlated with Post-Treatment Reduction in Pulmonary Function and Toxicity After Thoracic Radiation for Non Small Cell Lung Cancer .Abstract ASTRO 2013 Oral presentation 
  8. Samuels SE, Lipitz JB, Wang J, Dahl G, Muller KJ. Arachidonic acid closes innexin/pannexin channels and thereby inhibits microglia cell movement to a nerve injury.  Dev Neurobiol. 2013 Aug;73(8):621-31.
  9. Vainshtein JM, Schipper M, Zalupski M, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E. Prognostic Significance of CA 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated with Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full Dose Gemcitabine: Analysis of a Prospective Phase I/II Dose Escalation Study. Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):721-8.
    Vainshtein J, Eisbruch A. Function, Muscles, and Sparing by IMRT for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):577-8. Editorial.
  10. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng FY, Hamstra DA. The Interval to Biochemical Failure is Prognostic for Metastasis, Prostate Cancer Specific, and Overall
    Jeffrey M. Vainshtein, MD 5 Last Update: 9/28/2013
  11. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng FY, Hamstra DA. The Interval to Biochemical Failure is Prognostic for Metastasis, Prostate Cancer Specific, and Overall
    Mortality Following Salvage Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):554-61.
  12. Shilkrut M, McLaughlin P, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to Biochemical Failure Predicts Clinical Outcomes in Patients with High-Risk Prostate Cancer Treated by Combined-Modality Radiotherapy. Int J Radiat Oncol Biol Phys. 2013 Jul 12;86(4):721-8.
    Demiroz C, Vainshtein JM*, Koukourakis G, Gutfeld O, Prince M, Bradford C, Wolf G, McLean S, Worden F, Chepeha D, Schipper MJ, McHugh J, Eisbruch A. Head & Neck Squamous Cell Carcinoma of Unknown Primary: Neck Dissection and Radiotherapy or Definitive Radiotherapy. Head Neck . 2013 Aug 30. [Epub ahead of print]. [*Co-first authors].
  13. Vainshtein JM, Wu VF, Spector ME, Bradford CB, Wolf GT, Worden FP. Chemoselection: A Paradigm for Optimization of Organ Preservation in Locally Advanced Larynx Cancer. Expert Rev Anticancer Ther. 2013 Sep;13(9):1053-64.


  1. Baumann BC, Kao GD, Mahmud A, Harada T, Swift J, Chapman C, Xu X, Discher DE, Dorsey JF. Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy. Oncotarget. 2012 Dec 23.
  2. Chapman CH, Hwang WT, Deville C. Diversity Based on Race, Ethnicity, and Sex, of the US Radiation Oncology Physician Workforce. Int J Radiat Oncol Biol Phys. 2012 Nov 1. doi:pii: S0360-3016(12)03406-2.
  3. Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell selfrenewal and leukemia suppression 2012. Cell Stem Cell 11(3):415-428.
  4. Kapadia NS, Mamet R, Zornosa C, Niland JC, D'Amico TA, Hayman JA. Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer. Cancer, January 17, 2012
  5. Kapadia NS, Vigneau FD, Quarshie WO, Schwartz AG, Kong FM. Patterns of practice and outcomes for stage I non-small cell lung cancer (NSCLC): Analysis of SEER-17 data 1999-2008. ASTRO 2012, Multidisciplinary Symposium in Thoracic Oncology,
  6. Kapadia NS, Oh K, Hung J, Hamstra D. Assessment Of Bone Growth Effects Among Medulloblastoma Patients Treated With Electron Vs Photon Spinal Irradiation. ASTRO, 2012.
  7. Kong FM, Quarshie W, Kapadia NS, Bi, N, Vigneau FD,. Role of Radiation Therapy in Small Cell Lung Cancer (SCLC): Analysis of SEER-17 Data. ASTRO 2012, Multidisciplinary Symposium in Thoracic Oncology, 2012.
  8. Speers C, Lawrence T. Management of Anal Carcinoma, Oncology for the Primary Care Clinician, book chapter, Wolters Kluwer Health Lippincott Williams & Wilkins, 2012
  9. Speers C, Hayman J, Kalemkarian G, Kong S, Reddy R, Lin J, Quint L., Imaging in Thoracic Oncology: Case Studies from Multidisciplinary Thoracic Tumor Board Cancer Imaging, Cancer Imaging, in press
  10. Vainshtein J, Abu-Isa E, Olson K, Ray ME, Sandler HM, Normolle D, Litzenberg DW, Masi K, Pan C, Hamstra DA. Randomized Phase II Trial of Urethral Sparing Intensity Modulated Radiation Therapy in Low-risk Prostate Cancer: Implications for Focal Therapy. Radiation Oncology 2012 Jun 9; 7:82.
  11. Griffin GR, Abuzeid W, Vainshtein J, Kim JC. Inferior Objective Outcomes Following Temporalis Tendon Transfer in Radiated Patients. Arch Facial Plast Surg. 2012 Nov;14(6):395-402.
  12. Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr, Glick GD. Distinct metabolic
    programs in activated T cells: opportunities for selective immunomodulation. Immunol
    Rev. 2012 Sep;249(1):104-15
  13. Glick GD, Rossignol R, Lyssiotis CA, Wahl DR, Lesch C, Sanchez B, Liu X, Hao LY,
    Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer CA, Boros L, Opipari AW. T
    Cells Activated In Vivo Rely on Anaplerosis and Oxidative Phosphorylation in
    Preference to Aerobic Glycolysis. Proc Natl Acad Sci. Submitted


  1. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e93-9. Epub 2011 May 17.
    Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs
    Late Complication Probabilities and Dosimetric Correlates.
    Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR,
    Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK.
  2. Anal Biochem. 2011 Oct 1;417(1):57-64. Epub 2011 May 30.
    Molecular imaging of epidermal growth factor receptor kinase activity.
    Khan AP, Contessa JN, Nyati MK, Ross BD, Rehemtulla A.
  3. Mol Cancer Ther. 2011 Oct;10(10):1807-17. Epub 2011 Aug 22.
    A Novel Kinase Inhibitor of FADD Phosphorylation Chemosensitizes through the
    Inhibition of NF-{kappa}B.
    Schinske KA, Nyati S, Khan AP, Williams TM, Johnson TD, Ross BD, Pérez Tomás R,
    Rehemtulla A.
  4. Transl Oncol. 2011 Oct;4(5):282-92. Epub 2011 Oct 1.
    Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human
    Pancreatic Cancer Cells.
    Yao H, Zeng ZZ, Fay KS, Veine DM, Staszewski ED, Morgan M, Wilder-Romans K,
    Williams TM, Spalding AC, Ben-Josef E, Livant DL.
  5. Transl Oncol. 2011 Aug;4(4):227-33. Epub 2011 Aug 1.
    Ablation of breast cancer stem cells with radiation.
    Zielske SP, Spalding AC, Wicha MS, Lawrence TS.
  6. Int J Radiat Oncol Biol Phys. 2011 Jun 4. [Epub ahead of print]
    Continued Benefit to Androgen Deprivation Therapy for Prostate Cancer Patients
    Treated with Dose-Escalated Radiation Therapy Across Multiple Definitions of
    High-Risk Disease.
    Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.
  7. Int J Radiat Oncol Biol Phys. 2011 Jun 1. [Epub ahead of print]
    Greater Postimplant Swelling in Small-Volume Prostate Glands: Implications for
    Dosimetry, Treatment Planning, and Operating Room Technique.
    Chung E, Stenmark MH, Evans C, Narayana V, McLaughlin PW.
  8. Int J Radiat Oncol Biol Phys. 2011 May 5. [Epub ahead of print]
    Concurrent Androgen Deprivation Therapy During Salvage Prostate Radiotherapy
    Improves Treatment Outcomes in High-Risk Patients.
    Soto DE, Passarelli MN, Daignault S, Sandler HM.
  9. Cancer J. 2011 May-Jun;17(3):151-4.
    Advances in imaging: target delineation.
    Hunter KU, Eisbruch A.
  10. Int J Radiat Oncol Biol Phys. 2011 Apr 12. [Epub ahead of print]
    Contralateral Breast Dose After Whole-Breast Irradiation: An Analysis by
    Treatment Technique.
    Williams TM, Moran JM, Hsu SH, Marsh R, Yanke B, Fraass BA, Pierce LJ.
  11. Int J Radiat Oncol Biol Phys. 2011 Apr 4. [Epub ahead of print]
    Outcomes of Multidisciplinary Management in Pediatric Low-Grade Gliomas.
    Oh KS, Hung J, Robertson PL, Garton HJ, Muraszko KM, Sandler HM, Hamstra DA.


  12. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):727-33. Epub 2009 Sep 23.
    Evaluating and reporting dysphagia in trials of chemoirradiation for
    head-and-neck cancer.
    Gluck I, Feng FY, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A.
  13. Clin Cancer Res. 2010 Jun 15;16(12):3205-14. Epub 2010 Apr 22.
    Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a
    novel target for cancer therapy.
    Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS.
  14. Breast Cancer Res Treat. 2010 Jun;121(2):389-98. Epub 2010 Apr 22.
    Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer:
    comparison of breast conservation and mastectomy.
    Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG,
    Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek
  15. J Clin Oncol. 2010 Jun 1;28(16):2732-8. Epub 2010 Apr 26.
    Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with
    oropharyngeal cancer: clinical and functional results.
    Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME,
    Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A.
  16. Transl Oncol. 2010 Jun 1;3(3):149-52.
    Loss of tumor-initiating cell activity in cyclophosphamide-treated breast
    Zielske SP, Spalding AC, Lawrence TS.
  17. Neoplasia. 2010 May;12(5):357-65.
    GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.
    Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman
    H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, Ben-Josef E.
  18. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):369-78. Epub 2009 Jun 8.
    Radiographic and anatomic basis for prostate contouring errors and methods to
    improve prostate contouring accuracy.
    McLaughlin PW, Evans C, Feng M, Narayana V.
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    48374-1236, USA.
  19. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):71-8.
    Unacceptable cosmesis in a protocol investigating intensity-modulated
    radiotherapy with active breathing control for accelerated partial-breast
    Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA, Pierce LJ.


  20. Radiother Oncol. 2009 Dec;93(3):510-5. Epub 2009 Jun 10.
    Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head
    and neck cancer and their dose-effect relationships: MRI-based study.
    Popovtzer A, Cao Y, Feng FY, Eisbruch A.
  21. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1196-200. Epub 2009 Mar 26.
    Radiotherapy for pancreatic neuroendocrine tumors.
    Contessa JN, Griffith KA, Wolff E, Ensminger W, Zalupski M, Lawrence TS,
    Ben-Josef E.
  22. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1060-3. Epub 2009 Mar 21.
    Mucositis versus tumor control: the therapeutic index of adding chemotherapy to
    irradiation of head and neck cancer.
    Lee IH, Eisbruch A.
  23. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):294-301. Epub 2009 Jun 18.
    Accelerated partial breast irradiation: what is dosimetric effect of advanced
    technology approaches?
    Moran JM, Ben-David MA, Marsh RB, Balter JM, Griffith KA, Hayman JA, Pierce LJ.
  24. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1342-7. Epub 2009 Jan 8.
    The pattern of failure after reirradiation of recurrent squamous cell head and
    neck cancer: implications for defining the targets.
    Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME, Bradford CR,
    Eisbruch A.
  25. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):884-91. Epub 2009 Apr 22.
    Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor
    position should be used with caution.
    Feng M, Balter JM, Normolle D, Adusumilli S, Cao Y, Chenevert TL, Ben-Josef E.
  26. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):790-5. Epub 2009 Feb 21.
    Time to treatment in patients with stage III non-small cell lung cancer.
    Wang L, Correa CR, Hayman JA, Zhao L, Cease K, Brenner D, Arenberg D, Curtis J,
    Kalemkerian GP, Kong FM.
  27. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):511-7. Epub 2008 Oct 30.
    Combined-modality therapy with gemcitabine and radiation therapy as a bladder
    preservation strategy: long-term results of a phase I trial.
    Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM.
  28. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):38-46. Epub 2008 Oct 19.
    Skin cancer of the head and neck with perineural invasion: defining the clinical
    target volumes based on the pattern of failure.
    Gluck I, Ibrahim M, Popovtzer A, Teknos TN, Chepeha DB, Prince ME, Moyer JS,
    Bradford CR, Eisbruch A.
  29. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1596-601.
    Influence of rotations on dose distributions in spinal stereotactic body
    radiotherapy (SBRT).
    Gutfeld O, Kretzler AE, Kashani R, Tatro D, Balter JM.
  30. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1383-90. Epub 2008 Oct 17.
    The effect of radiation dose and chemotherapy on overall survival in 237 patients
    with Stage III non-small-cell lung cancer.
    Wang L, Correa CR, Zhao L, Hayman J, Kalemkerian GP, Lyons S, Cease K, Brenner D,
    Kong FM.
  31. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1228-34.
    Using fluorodeoxyglucose positron emission tomography to assess tumor volume
    during radiotherapy for non-small-cell lung cancer and its potential impact on
    adaptive dose escalation and normal tissue sparing.
    Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK.
  32. Radiother Oncol. 2009 Mar;90(3):389-94. Epub 2008 Oct 30.
    Determining if pretreatment PSA doubling time predicts PSA trajectories after
    radiation therapy for localized prostate cancer.
    Soto DE, Andridge RR, Pan CC, Williams SG, Taylor JM, Sandler HM.
  33. Transl Oncol. 2009 Mar;2(1):8-20.
    alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in
    Endothelial Cells to Stimulate Angiogenesis.
    Zeng ZZ, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, Spalding AC,
    Livant DL.
  34. Can J Urol. 2009 Feb;16(1):4495-7.
    Androgen deprivation therapy for patients with prostate carcinoma and Parkinson's
    disease: case report and review of literature.
    Elshaikh MA, Underwood W, Soto DE.
  35. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):334-40.
    Evaluating the relationships between rectal normal tissue complication
    probability and the portion of seminal vesicles included in the clinical target
    volume in intensity-modulated radiotherapy for prostate cancer.
    Gluck I, Vineberg KA, Ten Haken RK, Sandler HM.
  36. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):479-85. Epub 2008 Oct 1.
    Association of 11C-methionine PET uptake with site of failure after concurrent
    temozolomide and radiation for primary glioblastoma multiforme.
    Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, Ten Haken RK,
    Lawrence TS, Cao Y, Tsien C.
  37. Clin Cancer Res. 2009 Jan 15;15(2):589-96.
    Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
    Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA.
  38. Urology. 2009 Jan;73(1):158-62. Epub 2008 Aug 22.
    No effect of statins on biochemical outcomes after radiotherapy for localized
    prostate cancer.
    Soto DE, Daignault S, Sandler HM, Ray ME.


  39. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1287-90.
    Early prediction of outcome in advanced head-and-neck cancer based on tumor blood
    volume alterations during therapy: a prospective study.
    Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T,
    Bradford C, Mukherji SK, Eisbruch A.
  40. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1408-15. Epub 2008 May 19.
    Predicting biochemical failure and overall survival through intratherapy PSA
    changes during definitive external beam radiotherapy.
    Soto DE, Andridge RR, Taylor JM, McLaughlin PW, Sandler HM, Pan CC.
  41. Transl Oncol. 2008 Dec;1(4):195-201.
    Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and
    Cytotoxicity of Radiation against Endothelial Cells.
    Spalding AC, Zeitlin BD, Wilder-Romans K, Davis ME, Nor JE, Lawrence TS,
    Ben-Josef E.
  42. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):610-6.
    Evaluation of multiple breathing states using a multiple instance geometry
    approximation (MIGA) in inverse-planned optimization for locoregional breast
    Lin A, Moran JM, Marsh RB, Balter JM, Fraass BA, McShan DL, Kessler ML, Pierce
  43. Radiother Oncol. 2008 Oct;89(1):13-8. Epub 2008 Jun 12.
    Correlation between pretreatment FDG-PET biological target volume and anatomical
    location of failure after radiation therapy for head and neck cancers.
    Soto DE, Kessler ML, Piert M, Eisbruch A.
  44. Radiother Oncol. 2008 Sep;88(3):398-402. Epub 2008 Jun 19.
    Radiotherapy using a water bath in the treatment of Bowen's disease of the digit.
    Herman JM, Pierce LJ, Sandler HM, Griffith KA, Jabbari S, Hiniker SM, Johnson TM.
  45. Cancer. 2008 Aug 1;113(3):648-53.
    Toxicity of radiotherapy in patients with collagen vascular disease.
    Lin A, Abu-Isa E, Griffith KA, Ben-Josef E.
  46. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1295-301. Epub 2008 May 9.
    In patients experiencing biochemical failure after radiotherapy, pretreatment
    risk group and PSA velocity predict differences in overall survival and
    biochemical failure-free interval.
    Soto DE, Andridge RR, Pan CC, Williams SG, Taylor JM, Sandler HM.
  47. Cancer Res. 2008 May 15;68(10):3803-9.
    Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling
    in tumor cells.
    Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS.
  48. Clin Cancer Res. 2008 Apr 1;14(7):2161-70.
    Evaluation of D-methionine as a novel oral radiation protector for prevention of
    Vuyyuri SB, Hamstra DA, Khanna D, Hamilton CA, Markwart SM, Campbell KC, Sunkara
    P, Ross BD, Rehemtulla A.
  49. Expert Rev Anticancer Ther. 2008 Apr;8(4):633-44.
    Advances in radiation therapy of head and neck cancer.
    Popovtzer A, Eisbruch A.
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    48109-0010, USA.
  50. J Urol. 2008 Mar;179(3):1072-6; discussion 1076. Epub 2008 Jan 18.
    The impact of treatment choice for localized prostate cancer on response to
    phosphodiesterase inhibitors.
    Lee IH, Sadetsky N, Carroll PR, Sandler HM.
  51. Transl Oncol. 2008 Mar;1(1):36-43.
    Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer
    Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS.
  52. Transl Oncol. 2008 Mar;1(1):44-9.
    Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection
    in a pancreatic cancer model.
    Morgan M, El Shaikh MA, Abu-Isa E, Davis MA, Lawrence TS.
  53. Urology. 2008 Feb;71(2):313-7.
    Impact of common iliac nodal treatment on radiation outcomes in localized
    prostate cancer.
    Soto DE, Glaser S, Roberts RH, Schipper MJ, McLaughlin PW, Ray ME, Sandler HM,
    Pan CC.
  54. Semin Radiat Oncol. 2008 Jan;18(1):23-34.
    Combined permanent implant and external-beam radiation therapy for prostate
    Soto DE, McLaughlin PW.
  55. Semin Radiat Oncol. 2008 Jan;18(1):7-14.
    Hormone therapy and radiotherapy for intermediate risk prostate cancer.
    Lee I, Sandler H.


  56. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6827-33.
    Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity
    in pancreatic cancer.
    Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E.
  57. Clin Colorectal Cancer. 2007 Nov;6(10):716-9.
    Intensity-modulated radiation therapy for the treatment of anal cancer.
    Lin A, Ben-Josef E.
  58. Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):214-20.
    Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function
    to ionizing radiation.
    Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M.
  59. Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):103-10. Epub 2007 Jun 7.
    Long-term outcomes after radiotherapy for retroperitoneal and deep truncal
    Feng M, Murphy J, Griffith KA, Baker LH, Sondak VK, Lucas DR, McGinn CJ, Ray ME.
  60. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98. Epub 2007 Jun 7.
    Intensity-modulated radiotherapy of head and neck cancer aiming to reduce
    dysphagia: early dose-effect relationships for the swallowing structures.
    Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A.
  61. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1417-23. Epub 2007 Apr 6.
    Predictive factors for late genitourinary and gastrointestinal toxicity in
    patients with prostate cancer treated with adjuvant or salvage radiotherapy.
    Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ,
    Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM.
  62. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1059-64. Epub 2007 Mar 29.
    Perineural invasion is a marker for pathologically advanced disease in localized
    prostate cancer.
    Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, Sandler HM.
  63. Breast J. 2007 Jul-Aug;13(4):392-400.
    Long-term results of conservative surgery and radiotherapy for ductal carcinoma
    in situ using lung density correction: the University of Michigan experience.
    Ben-David MA, Sturtz DE, Griffith KA, Douglas KR, Hayman JA, Lichter AS, Pierce
  64. 64. Cancer J. 2007 Jul-Aug;13(4):243-6.
    Limited-stage extrapulmonary small cell carcinoma: outcomes after modern
    chemotherapy and radiotherapy.
    Soto DE, Eisbruch A.
  65. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):541-6.
    Short-term displacement and reproducibility of the breast and nodal targets under
    active breathing control.
    Moran JM, Balter JM, Ben-David MA, Marsh RB, Van Herk M, Pierce LJ.
  66. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):396-402. Epub 2007 Feb 22.
    Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy
    for head and neck cancer: likely contributions of both dental care and improved
    dose distributions.
    Ben-David MA, Diamante M, Radawski JD, Vineberg KA, Stroup C, Murdoch-Kinch CA,
    Zwetchkenbaum SR, Eisbruch A.
  67. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):253-8.
    Respiratory motion of the heart and positional reproducibility under active
    breathing control.
    Jagsi R, Moran JM, Kessler ML, Marsh RB, Balter JM, Pierce LJ.
  68. Urology. 2007 May;69(5):936-40.
    Percent positive biopsy cores as a prognostic factor for prostate cancer treated
    with external beam radiation.
    Spalding AC, Daignault S, Sandler HM, Shah RB, Pan CC, Ray ME.
  69. Clin Cancer Res. 2007 Apr 15;13(8):2512-8.
    Effect of epidermal growth factor receptor inhibitor class in the treatment of
    head and neck cancer with concurrent radiochemotherapy in vivo.
    Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence
    TS, Nyati MK.
  70. Semin Oncol. 2007 Apr;34(2):129-34.
    Multimodality bladder preservation therapy for muscle-invasive bladder tumors.
    Fernando SA, Sandler HM.
  71. J Clin Oncol. 2007 Mar 10;25(8):1009-13.
    Future issues in highly conformal radiotherapy for head and neck cancer.
    Feng M, Eisbruch A.
  72. Cancer Biol Ther. 2007 Mar;6(3):463-4. Epub 2007 Mar 20.
    Using ErbB2-negative status to direct therapy in locally advanced breast cancer.
    Spalding AC, Contessa JN.
  73. Med Phys. 2007 Feb;34(2):521-9.
    Potential for dose-escalation and reduction of risk in pancreatic cancer using
    IMRT optimization with lexicographic ordering and gEUD-based cost functions.
    Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS,
    Haken RK, Ben-Josef E.

Back to Top